Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hexaxim Vaccine
Hexaxim · 1 trial · 6 indications
Solicited injection site reactions: tenderness, erythema, and swelling (and extensive limb swelling for booster dose). Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability
| Arm | Type | Description |
|---|---|---|
| DTaP-IPV-HB-PRP~T Vaccine | EXPERIMENTAL | All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP\~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age). |
| Name | Type | Description |
|---|---|---|
| Hexaxim® | BIOLOGICAL | DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 61 to 91 days on the day of the first study visit * Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥2.5 kg * Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if ...
Hexaxim is a vaccine used for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infections. It is administered as a three-dose primary series at 2, 3, and 4 months of age, followed by a booster dose at 16 to 17 months of age.
Hexaxim is developed by Sanofi, a company listed on the stock exchange under the ticker symbol SNY. The vaccine is being studied for use in infants to protect against multiple infectious diseases.
Hexaxim is in Phase 3 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. A Phase 3 clinical trial has been completed to evaluate its immunogenicity and safety.
Hexaxim has been studied in one completed Phase 3 clinical trial, identified as NCT02428491. This trial enrolled 354 participants in Vietnam and evaluated the vaccine's immunogenicity and safety when given as a three-dose primary series followed by a booster dose in infants.
Yes, Hexaxim is also known as Hexaxim Vaccine. Both names refer to the same vaccine product developed by Sanofi for the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b infections.
Hexaxim is a vaccine that targets multiple pathogens, including those causing diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. It works by stimulating the immune system to produce protection against these infectious diseases.